TEVA

MKT CAP:$36B

Teva Pharmaceutical Industries Limited

Market Cap

$36B

Healthcare·Drug Manufacturers - Specialty & Generic·🇮🇱 Israel·NYSE

Healthcare·Drug·🇮🇱·NYSE

Stock Price

$30.75-$0.20 (-0.66%)

Apr 24, 2026

Company Details

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The com...

CEO

Richard D. Francis

IPO Date

Feb 16, 1982

Website

www.tevapharm.com

Key Metrics TTM

Revenue

$17.0B

— YoY

Net Income

$240M

EPS (Diluted)

$0.16

Free Cash Flow

$1.2B

Revenue / Share

$14.52

Gross Margin

51.7%

Operating Margin

5.4%

Net Margin

1.4%

FCF Margin

6.9%

P/S

2.1x

P/E

148.8x

Earnings Reports

Q1 2026

Apr 29, 2026

PENDING

Q4 2025

Feb 3, 2026

$4.7BEPS $0.41

Q3 2025

Nov 5, 2025

$4.5BEPS $0.37

Q2 2025

Jul 30, 2025

$4.2BEPS $0.24

Q1 2022

May 3, 2022

$3.7BEPS -$0.86

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 16	$6.5B	$3.4B	-$137M
Q2 17	$5.7B	$2.8B	-$5.7B
Q3 20	$4.0B	$1.9B	-$4.3B
Q1 22	$3.7B	$1.7B	-$713M
Q2 25	$4.2B	$2.1B	$455M
Q3 25	$4.5B	$2.3B	$882M
Q4 25	$4.7B	$2.7B	$300M

Valuation

Quarter	P/S	P/E
Q4 16	—	—
Q2 17	—	—
Q3 20	—	—
Q1 22	0.5x	—
Q2 25	1.1x	—
Q3 25	1.4x	—
Q4 25	2.1x	150.8x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 16	$1.4B	$1.1B
Q2 17	$741M	$548M
Q3 20	$307M	$164M
Q1 22	-$49M	-$206M
Q2 25	$227M	$131M
Q3 25	$369M	$233M
Q4 25	$1.2B	$1.0B

Capital Expenditures

Quarter	CapEx
Q4 16	$333M
Q2 17	$193M
Q3 20	$143M
Q1 22	$157M
Q2 25	$96M
Q3 25	$136M
Q4 25	$142M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 25	-35.7%	-43.9%
Q3 25	-21.2%	-68.5%
Q4 25	+18.4%	-47.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 16	$41M	0.6%
Q2 17	$35M	0.6%
Q3 20	$29M	0.7%
Q1 22	$24M	0.7%
Q2 25	$38M	0.9%
Q3 25	$34M	0.8%
Q4 25	$51M	1.1%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 16	$684M	$311M	$1.1B
Q2 17	$486M	$272M	$960M
Q3 20	$258M	$279M	$605M
Q1 22	$225M	$296M	$584M
Q2 25	$244M	$305M	$654M
Q3 25	$256M	$317M	$656M
Q4 25	$267M	$367M	$753M

Revenue Segments

Quarter	Distribution Service	License	Product	Product and Service, Other
Q3 20	$350M	$27M	$3.4B	$174M
Q1 22	$358M	$38M	$3.1B	$129M
Q2 25	$377M	$46M	$3.6B	$117M
Q3 25	$406M	$46M	$3.9B	$121M
Q4 25	$384M	$550M	$3.7B	$109M

Revenue by Geography

Quarter	Europe Segment	International Markets	United States Segment
Q3 25	$1.2B	$557M	$2.5B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$2.2B	$0	$2.2B
Q2 22	$2.1B	$0	$2.1B
Q3 22	$2.2B	$0	$2.2B
Q4 22	$2.8B	$0	$2.8B
Q1 23	$2.1B	$0	$2.1B
Q2 23	$2.7B	$0	$2.7B
Q3 23	$2.2B	$0	$2.2B
Q4 23	$3.2B	$0	$3.2B
Q1 24	$3.0B	$0	$3.0B
Q2 24	$2.3B	$0	$2.3B
Q3 24	$3.3B	$0	$3.3B
Q4 24	$3.3B	$0	$3.3B
Q1 25	$1.7B	$0	$1.7B
Q2 25	$2.2B	$0	$2.2B
Q3 25	$2.2B	$0	$2.2B
Q4 25	$3.6B	$0	$3.6B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 16	1.01B	—	—
Q2 17	1.02B	+0.2%	—
Q3 20	1.10B	+7.8%	—
Q1 22	1.11B	+1.0%	—
Q2 25	1.16B	+4.9%	+14.4%
Q3 25	1.16B	+0.3%	+14.5%
Q4 25	1.17B	+0.8%	+7.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 16	$114.0K	57K
Q2 17	$99.8K	57K
Q3 20	$99.4K	40K
Q1 22	$97.5K	38K
Q2 25	$113.4K	37K
Q3 25	$121.6K	37K
Q4 25	$138.6K	34K

Revenue / Employee